ImmuVia
ImmuVia is a privately held, pre-revenue Cambridge, MA biotech developing payload-free bispecific antibody therapeutics built on its Cancerlysin™ DR5 super-clustering platform, targeting MUC16-positive solid tumors (IMV-M™) and hematologic malignancies.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What ImmuVia does
ImmuVia is a privately held, pre-revenue biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts, that develops bispecific antibody therapeutics designed to induce tumor cell apoptosis without cytotoxic payloads. The company's foundational technology is the Cancerlysin™ platform, which engineers bispecific antibodies that bind a tumor-selective antigen (such as MUC16) on the cancer cell surface and use it as a scaffold to super-cluster DR5 death receptors, triggering the extrinsic apoptosis pathway. This mechanism is payload-free, immune-sparing, and does not require internalization — positioning ImmuVia's candidates as biologically orthogonal to antibody-drug conjugates (ADCs) and active in tumors with low-to-moderate antigen expression where ADCs are typically ineffective. The lead asset, IMV-M™, is a MUC16×DR5 bispecific antibody targeting non-small cell lung, ovarian, and pancreatic cancers and is currently in IND-enabling studies with first-in-human dosing projected within 12 months, with Phase 1 planned under Dr. Daniel Von Hoff at leading U.S. cancer centers. Two additional programs extend the platform: IMV-C (colorectal and gastric cancers, wholly owned, preclinical) and IMV-5 (acute myeloid leukemia, advancing on a partnering track).
ImmuVia's commercial strategy is a hybrid of clinical advancement and platform partnering. The company plans to run its own Phase 1 for IMV-M™, then advance wholly-owned programs through clinical development toward commercialization, while simultaneously seeking strategic partners to extend the Cancerlysin™ platform to new tumor-selective antigens and to develop indication-specific or regional collaborations. Revenue, when it materializes, is expected to come from licensing royalties, milestone payments, and partnership economics rather than direct product sales in the near term. The company is led by co-founders Iosif M. Gershteyn (CEO) and Victor S. Goldmacher (CSO), with a scientific team whose members are inventors of three FDA-approved antibody therapeutics (Kadcyla®, Elahere™, Sarclisa®) and who collectively hold 128+ issued US patents and 100+ publications.
The company has built scientific credibility through three peer-reviewed publications (Antibody Therapeutics 2024 and 2026; Nature Scientific Reports 2025), independent efficacy replication at TGen/City of Hope, and clean NHP safety at 4× therapeutic dose with zero hepatotoxicity. It holds an international PCT patent application for IMV-M™ and was selected for the Texas Medical Center 2025 Accelerator for Cancer Therapeutics. No funding rounds are disclosed in the available sources, which is a notable data point for a private biotech at IND-enabling stage.
ImmuVia firmographics
Firmographics- Name
- ImmuVia
- Legal name
- ImmuVia, Inc.
- Website
- https://www.immuvia.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ImmuVia is a privately held, pre-revenue Cambridge, MA biotech developing payload-free bispecific antibody therapeutics built on its Cancerlysin™ DR5 super-clustering platform, targeting MUC16-positive solid tumors (IMV-M™) and hematologic malignancies.
- Ownership category
- akta.pro rank
ImmuVia industry classification
Industry- Product category
- Bispecific Antibody Therapeutics / Oncology Biologics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
Keywords
Where ImmuVia is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ImmuVia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pipeline development and partnering: Pre-revenue biotech company developing a pipeline of bispecific antibody therapeutics. Revenue strategy includes partnering on new targets, regional collaborations, and advancement of wholly-owned programs through clinical development to commercialization.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
ImmuVia product offering
Product offeringCore offering
ImmuVia develops bispecific antibody therapeutics using its proprietary Cancerlysin™ platform, which super-clusters DR5 death receptors on tumor cells to trigger apoptosis without payloads or immune activation. The lead program IMV-M™ is a MUC16×DR5 bispecific antibody for NSCLC, ovarian, and pancreatic cancers, currently at IND-enabling stage with first-in-human dosing planned within 12 months. Additional programs include IMV-C (colorectal/gastric) and IMV-5 (acute myeloid leukemia, on a partnering track).
Product overview
ImmuVia is a biopharmaceutical company developing a portfolio of Cancerlysin™ bispecific antibody therapeutics built on a proprietary apoptosis-inducing platform. The lead product IMV-M™ (MUC16×DR5 bispecific) is at IND-enabling stage for NSCLC, ovarian, and pancreatic cancers. Additional programs include IMV-C for colorectal/gastric cancer and IMV-5 for acute myeloid leukemia (the latter advancing on a partnering track). The Cancerlysin™ platform serves as the foundational technology enabling expansion to new tumor-selective antigen targets.
Differentiator
Problem solved
Functional benefit
Brands
- Cancerlysin™: Platform technology that applies apoptosis engine to new tumor-selective antigens; turns any clinically validated tumor antigen into a scaffold for tumor-restricted DR5 super-clustering
Products and services
- IMV-M™
Quantifiable outcome
- Clean NHP safety at 4× therapeutic dose with zero hepatotoxicity
- +3 more outcomes
Companies that use ImmuVia
Customer profileSegments2 records
Ideal customer profiles2 records
ImmuVia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ImmuVia partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered supporting, core and minor.
- QuantorisupportingQuantori's Q-Scientist platform selected to accelerate IMV-M™ development, providing computational and data science capabilities to support the IND-enabling and clinical development process.
- TGen (City of Hope)coreIndependent foundation-funded study replicated IMV-M™'s anti-tumor efficacy at TGen, part of City of Hope. Dr. Daniel Von Hoff's laboratory conducted the replication study, validating the company's preclinical data independently.
- New tumor target partners (seeking)minorImmuVia is seeking partners to extend the Cancerlysin™ platform to new tumor-selective antigens. Partners can bring clinically validated antigens while ImmuVia builds the Cancerlysin™ therapeutic.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
ImmuVia competitors and assessment
Company assessmentEmerging players
- ProfoundBio: Clinical-stage developer of next-generation ADCs in oncology with multiple wholly-owned programs targeting solid tumors. Comparable to ImmuVia as a focused antibody-therapeutics company in oncology with platform-based pipeline expansion, though using payload-based ADC technology versus ImmuVia's payload-free bispecific approach.
- Compass Therapeutics: Clinical-stage oncology biotech with a portfolio of bispecific antibodies including DR5-targeting candidates (e.g., CT900). Highly comparable to ImmuVia in modality (bispecific antibodies targeting DR5 in solid tumors) and stage, and serves as a useful benchmark for clinical translation of the DR5 bispecific thesis.
- Harpoon Therapeutics: Bispecific T-cell engager platform (TriTAC) oncology company (acquired by Merck). Comparable to ImmuVia as a clinical-stage bispecific antibody developer focused on solid tumors, addressing similar mechanism-of-action challenges around selectivity and tumor-restricted activity.
Direct peers
- ImmunoGen: Developer of Elahere (MUC16-targeting ADC) and Kadcyla — the same two FDA-approved antibody therapeutics the ImmuVia CSO and SAB helped invent. Directly comparable on the MUC16 ovarian-cancer target and on the antibody-therapeutics development playbook, though ImmunoGen's modality is payload-bearing ADCs versus ImmuVia's payload-free bispecific.
- MacroGenics: Clinical-stage biotech developing bispecific antibodies and ADCs in oncology, including prior DR5-targeting programs (e.g., enoblituzumab). Directly comparable as a bispecific/antibody-focused oncology company with DR5-targeting experience, addressing similar solid-tumor indications as ImmuVia.
- Mersana Therapeutics: Clinical-stage oncology company developing next-generation ADCs, including a MUC16 ADC program, with antibody payload and linker platforms. Directly comparable to ImmuVia as a MUC16-targeted solid-tumor developer with an antibody-based therapeutic platform, though using a different killing mechanism (payload vs. DR5 super-clustering).
Broad incumbents
- Genmab: Large biotech with multiple approved bispecific antibodies (e.g., Hemlibra via partnership, Epkinly) powered by the DuoBody bispecific platform. Comparable to ImmuVia as a leading bispecific antibody platform company in oncology and hematology, though at much greater scale and with an established commercial portfolio.
- Xencor: Clinical-stage biotech developing engineered bispecific antibodies (XmAb platform) in oncology and autoimmune disease. Comparable to ImmuVia as a bispecific antibody platform company pursuing multiple oncology programs, though Xencor's broader XmAb platform addresses additional immune-mediated mechanisms.
- Elahere / AbbVie (ImmunoGen, acquired): AbbVie acquired ImmunoGen and now commercializes Elahere (mirvetuximab soravtansine), the MUC16-targeting ADC. Comparable to ImmuVia as the established competitor in the same MUC16-positive ovarian cancer indication, against which IMV-M will be benchmarked on safety, efficacy, and combination potential.
- Zymeworks: Clinical-stage biotech with bispecific antibody platforms (Azymetric, zanidatamab) targeting oncology indications including HER2-driven tumors. Comparable to ImmuVia as a bispecific antibody platform developer in oncology, though at a more advanced clinical and commercial stage and focused on different tumor antigens.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
ImmuVia social profiles
Digital presenceImmuVia financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmuVia leadership team
Management profileNumber of profiles
Profiles11 records
ImmuVia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmuVia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmuVia
What does ImmuVia do?
ImmuVia develops bispecific antibody therapeutics using its proprietary Cancerlysin™ platform, which super-clusters DR5 death receptors on tumor cells to trigger apoptosis without payloads or immune activation. The lead program IMV-M™ is a MUC16×DR5 bispecific antibody for NSCLC, ovarian, and pancreatic cancers, currently at IND-enabling stage with first-in-human dosing planned within 12 months. Additional programs include IMV-C (colorectal/gastric) and IMV-5 (acute myeloid leukemia, on a partnering track).
Is ImmuVia a public or private company?
ImmuVia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ImmuVia founded?
ImmuVia was founded in 2017. It employs 1 to 10 people.
Where is ImmuVia based?
ImmuVia is headquartered in Cambridge, United States, in the North America region.
How does ImmuVia make money?
One revenue line is on record: pipeline development and partnering.
Who are ImmuVia's main competitors?
Emerging players on record are ProfoundBio, Compass Therapeutics and Harpoon Therapeutics. Direct peers are ImmunoGen, MacroGenics and Mersana Therapeutics. Broad incumbents are Genmab, Xencor, Elahere / AbbVie (ImmunoGen, acquired) and Zymeworks.
Does ImmuVia have an API?
No public API is recorded for ImmuVia.
What industry is ImmuVia in?
ImmuVia's product category is Bispecific Antibody Therapeutics / Oncology Biologics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325412 and its SIC code is 2836.